Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis.
Patient Prefer Adherence. 2023 Jun 14;17:1431-1439. doi: 10.2147/PPA.S411069. eCollection 2023.
Patient Prefer Adherence. 2023.
PMID: 37337517
Free PMC article.
[Family planning in men and women with multiple sclerosis. Analysis of the Andalusian Registry (2018-2022)].
Vidal-de Francisco D, Rosa-Garrido C, Ruiz-de Arcos M, Romero-Villarrubia A, Romero-Tellado M, Alonso-Torres AM, Delgado-Gil V, Agüera-Morales E, Díaz-Sánchez M, Piñar-Morales R, Muñoz-Fernández C, Pacheco-Cortegana EM, Durán-Ferreras E, Arnal-García MC, Mendibe-Bilbao MM, Rodríguez-Antigüedad A.
Vidal-de Francisco D, et al. Among authors: alonso torres am.
Rev Neurol. 2023 Jun 16;76(12):377-383. doi: 10.33588/rn.7612.2023149.
Rev Neurol. 2023.
PMID: 37303099
Free PMC article.
Spanish.
Item in Clipboard
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023.
Meca-Lallana JE, Martínez Yélamos S, Eichau S, Llaneza MÁ, Martín Martínez J, Peña Martínez J, Meca Lallana V, Alonso Torres AM, Moral Torres E, Río J, Calles C, Ares Luque A, Ramió-Torrentà L, Marzo Sola ME, Prieto JM, Martínez Ginés ML, Arroyo R, Otano Martínez MÁ, Brieva Ruiz L, Gómez Gutiérrez M, Rodríguez-Antigüedad Zarranz A, Sánchez-Seco VG, Costa-Frossard L, Hernández Pérez MÁ, Landete Pascual L, González Platas M, Oreja-Guevara C.
Meca-Lallana JE, et al. Among authors: alonso torres am.
Neurologia (Engl Ed). 2024 Mar;39(2):196-208. doi: 10.1016/j.nrleng.2024.01.003. Epub 2024 Jan 16.
Neurologia (Engl Ed). 2024.
PMID: 38237804
Free article.
Item in Clipboard
Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain.
Alonso Torres AM, Arévalo Bernabé AG, Becerril Ríos N, Hellín Gil MF, Martínez Sesmero JM, Meca Lallana V, Ramió-Torrentà L, Rodríguez-Antigüedad A, Gómez Maldonado L, Triana Junco I, Gómez-Barrera M, Espinoza Cámac N, Oyagüez I.
Alonso Torres AM, et al.
Pharmacoecon Open. 2023 May;7(3):431-441. doi: 10.1007/s41669-023-00394-2. Epub 2023 Feb 21.
Pharmacoecon Open. 2023.
PMID: 36802327
Free PMC article.
Item in Clipboard
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators.
Foley JF, et al.
Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25.
Lancet Neurol. 2022.
PMID: 35483387
Clinical Trial.
Item in Clipboard
Cite
Cite